Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

On May 27, the company announced the inking of an agreement to acquire SiteOne therapeutics. The company is acquiring the private biotech company in a deal worth up to $1 billion in cash and milestone ...

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which blocks the NaV1.8 sodium channel to treat pain. This target has ...

along with SiteOne Therapeutics, which recently closed a $100 million third-round financing to advance its NaV1.7 and NaV1.8 inhibitors into clinical development. Later this quarter, Tris is ...